# Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

> **NCT00911261** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 223 (actual)

## Conditions studied

- Chronic Pain
- Neuropathic Pain
- Cancer

## Interventions

- **DRUG:** Oxymorphone Extended Release

## Key facts

- **NCT ID:** NCT00911261
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2005-03
- **Final completion:** 2005-05
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2010-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911261, "Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00911261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*